Cochrane · systematic review · CD009371
Fingolimod for relapsing‐remitting multiple sclerosis
La Mantia, L, Tramacere, I, Firwana, B, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
10
No studies
2
Included studies
NR
No studies 2 · 16.7%Ungraded 0 · 0%Very low 1 · 8.3%Low 3 · 25%Moderate 6 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Fingolimod 0.5 mg versus placebo for relapsing‐remitting multiple sclerosis
Population: people with relapsing‐remitting multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes at 24 months Fingolimod 0.5 mg vs placebo | no estimate extracted | NR | No studies |
Participants free from relapse Fingolimod 0.5 mg vs placebo | RR 1.44 [1.28, 1.63] | 2 studies · 1556 participants | Moderate Downgraded: risk of bias |
Participants free from disability worsening Fingolimod 0.5 mg vs placebo | RR 1.07 [1.02, 1.11] | 2 studies · 1556 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Fingolimod 0.5 mg vs placebo | RR 1.42 [0.89, 2.25] | 2 studies · 1556 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Annualised relapse rate Fingolimod 0.5 mg vs placebo | Rate ratio 0.5 [0.4, 0.62] | 2 studies · 1556 participants | Moderate Downgraded: risk of bias |
Participants free from MRI gadolinium‐enhancing lesions Fingolimod 0.5 mg vs placebo | RR 1.36 [1.27, 1.45] | 2 studies · 1226 participants | Low Downgraded: risk of bias, imprecision |
Fingolimod 0.5 mg versus interferon beta‐1a for relapsing‐remitting multiple sclerosis
Population: people with relapsing‐remitting multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes at 12 months Fingolimod 0.5 mg vs interferon beta‐1a | no estimate extracted | NR | No studies |
Participants free from relapse Fingolimod 0.5 mg vs interferon beta‐1a | RR 1.18 [1.09, 1.27] | 1 study · 860 participants | Moderate Downgraded: imprecision |
Participants free from disability worsening Fingolimod 0.5 mg vs interferon beta‐1a | RR 1.02 [0.99, 1.06] | 1 study · 860 participants | Low Downgraded: imprecision |
Withdrawals due to adverse events Fingolimod 0.5 mg vs interferon beta‐1a | RR 1.51 [0.81, 2.8] | 1 study · 860 participants | Moderate Downgraded: imprecision |
Annualised relapse rate Fingolimod 0.5 mg vs interferon beta‐1a | Rate ratio 0.48 [0.34, 0.7] | 1 study · 860 participants | Moderate Downgraded: imprecision |
Participants free from MRI gadolinium‐enhancing lesions Fingolimod 0.5 mg vs interferon beta‐1a | RR 1.12 [1.05, 1.19] | 1 study · 728 participants | Moderate Downgraded: imprecision |